Generex Biotechnology Corporation Extends Clinical Trial Agreement for Testing its Synthetic Avian Influenza Vaccine

WORCESTER, Mass., March 3, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) announced today that it has extended its agreement with the Lebanese-Canadian Hospital in Beirut for follow-on testing of specific peptides screened over the past year. During the initial screening, it was found that all vaccine peptides were safe and well tolerated. The vaccine is being developed both in the U.S. and at the Lebanese-Canadian Hospital in Beirut. Dr. Alexander Abdelnoor, an immunologist at the American University of Beirut, is also participating as a consultant for the trials.